Unique ID issued by UMIN | UMIN000009108 |
---|---|
Receipt number | R000010681 |
Scientific Title | A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer. |
Date of disclosure of the study information | 2012/10/17 |
Last modified on | 2024/03/21 11:16:16 |
A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer.
HERPLET
A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer.
HERPLET
Japan |
women with HER2-positive and hormone receptor-positive breast cancer
Breast surgery |
Malignancy
NO
Evaluate the efficacy and safety of trastuzumab and paclitaxel with endocrine therapy as neoadjuvant therapy for HER2-positive and hormone receptor-positve breast cancer.
Safety,Efficacy
clinical response rate, tumor reduction rate
pathological CR rate, adverse event, breast conserving rate, relapse free survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Eligible premenopausal women receive tamoxifen 20mg/d orally and trastuzumab is given with a loading dose of 4 mg/kg; subsequent doses are 2 mg/kg every week. In addition, paclitaxel is given at a dose of 80 mg/m2; every week for 12 weeks.
Eligible postmenopausal women receive letrozole 2.5mg/d orally and trastuzumab is given with a loading dose of 4 mg/kg; subsequent doses are 2 mg/kg every week. In addition, paclitaxel is given at a dose of 80 mg/m2; every week for 12 weeks.
20 | years-old | <= |
75 | years-old | >= |
Female
1. Histologically confirmed invasive breast cancer
2. ER and or PgR-positive, HER2-positive
3. Measurable disease
4. Stage I , II or III
5. Age at 20 or older and at 75 or younger.
6. Performance status 0 or 1
7. Untreated breast cancer
8. Meet the cirteria of baseline labolatory parameters as below.
1) WBC 3500/mm3 or more, 10000/mm3 or less, Plt 100,000/mm3 or more, Hb 10g/dl or more
2) T.Bil 1mg/dl or less, GOT 60 IU/L or less, GPT 60 IU/L or less
9. Written informed consent
1. Other active malignancies
2. Hemorrhagic diathesis
3. History of cardiac infarction, valvular diseases of the heart and severe cardiac disfunction
4. Liver cirrhosis
5. Other medical conditions that could limit a patient's ability to undertake study therapy
50
1st name | |
Middle name | |
Last name | Tetsu Hayashida |
Keio University School of Medicine
Department of Surgery
35 Shinanomachi Shinjuku, Tokyo, Japan
03-5363-3802
tetsu@z7.keio.jp
1st name | |
Middle name | |
Last name | Tetsu Hayashida |
Keio University School of Medicine
Department of Surgery, breast group
35 Shinanomachi Shinjuku, Tokyo, Japan
03-5363-3802
tetsu@z7.keio.jp
Keio University School of Medicine
Keio University School of Medicine
Self funding
NO
2012 | Year | 10 | Month | 17 | Day |
Unpublished
Terminated
2012 | Year | 10 | Month | 13 | Day |
2012 | Year | 07 | Month | 30 | Day |
2012 | Year | 10 | Month | 17 | Day |
2022 | Year | 04 | Month | 30 | Day |
2012 | Year | 10 | Month | 13 | Day |
2024 | Year | 03 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010681
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |